The global pandemic of coronavirus disease 2019(COVID-19)changed dramatically all priorities on medical society and created several challenges for clinicians caring for patients with liver diseases.We performed a comp...The global pandemic of coronavirus disease 2019(COVID-19)changed dramatically all priorities on medical society and created several challenges for clinicians caring for patients with liver diseases.We performed a comprehensive review about how COVID-19 can affect the liver,the influence of liver diseases on the risk of developing severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and COVID-19 severity and also some strategies to overcome all the challenges clinicians have to face in the management of patients with liver diseases in a period of time when all the focus turned on COVID-19.We analyze the relationship between COVID-19 and non-alcoholic fatty liver disease,alcoholic liver disease,viral hepatitis,autoimmune liver disease,cirrhosis,hepatocellular carcinoma and liver transplantation,as well as the approach to SARS-CoV-2 vaccination.展开更多
Hepatobiliary manifestations are common in inflammatory bowel disease(IBD),with 30%of patients presenting abnormal liver tests and 5%developing chronic liver disease.They range from asymptomatic elevated liver tests t...Hepatobiliary manifestations are common in inflammatory bowel disease(IBD),with 30%of patients presenting abnormal liver tests and 5%developing chronic liver disease.They range from asymptomatic elevated liver tests to lifethreatening disease and usually follow an independent course from IBD.The pathogenesis of liver manifestations or complications and IBD can be closely related by sharing a common auto-immune background(in primary sclerosing cholangitis,IgG4-related cholangitis,and autoimmune hepatitis),intestinal inflammation(in portal vein thrombosis and granulomatous hepatitis),metabolic impairment(in non-alcoholic fatty liver disease or cholelithiasis),or drug toxicity(in drug induced liver injury or hepatitis B virus infection reactivation).Their evaluation should prompt a full diagnostic workup to identify and readily treat all complications,improving management and outcome.展开更多
文摘The global pandemic of coronavirus disease 2019(COVID-19)changed dramatically all priorities on medical society and created several challenges for clinicians caring for patients with liver diseases.We performed a comprehensive review about how COVID-19 can affect the liver,the influence of liver diseases on the risk of developing severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and COVID-19 severity and also some strategies to overcome all the challenges clinicians have to face in the management of patients with liver diseases in a period of time when all the focus turned on COVID-19.We analyze the relationship between COVID-19 and non-alcoholic fatty liver disease,alcoholic liver disease,viral hepatitis,autoimmune liver disease,cirrhosis,hepatocellular carcinoma and liver transplantation,as well as the approach to SARS-CoV-2 vaccination.
文摘Hepatobiliary manifestations are common in inflammatory bowel disease(IBD),with 30%of patients presenting abnormal liver tests and 5%developing chronic liver disease.They range from asymptomatic elevated liver tests to lifethreatening disease and usually follow an independent course from IBD.The pathogenesis of liver manifestations or complications and IBD can be closely related by sharing a common auto-immune background(in primary sclerosing cholangitis,IgG4-related cholangitis,and autoimmune hepatitis),intestinal inflammation(in portal vein thrombosis and granulomatous hepatitis),metabolic impairment(in non-alcoholic fatty liver disease or cholelithiasis),or drug toxicity(in drug induced liver injury or hepatitis B virus infection reactivation).Their evaluation should prompt a full diagnostic workup to identify and readily treat all complications,improving management and outcome.
